Learn About Lynch Syndrome
Lynch syndrome, often called hereditary nonpolyposis colorectal cancer (HNPCC), is an inherited disorder that increases the risk of many types of cancer. This includes cancers of the colon and rectum, which are collectively referred to as colorectal cancer. People with Lynch syndrome also have an increased risk of cancers of the stomach, small intestine, liver, gallbladder ducts, urinary tract, brain, and skin. Additionally, women with this disorder have an increased risk of cancer of the ovaries and the lining of the uterus (endometrial cancer). Women with Lynch syndrome have a higher overall risk of developing cancer than men with the condition because of these cancers of the female reproductive system. In individuals with Lynch syndrome who develop cancer, the cancer typically occurs in their 40s or 50s.
Variants that cause a disease or increase the risk for a disease are sometimes called pathogenic variants. Pathogenic variants in the MLH1, MSH2, MSH6, PMS2, or EPCAM genes can cause Lynch syndrome.
In the United States, it is estimated that 1 in 279 individuals have a genetic variant (also known as a mutation) that is associated with Lynch syndrome.
Lynch syndrome is typically inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to increase the risk of cancer. Although people with Lynch syndrome have a higher risk of cancer, not all people with Lynch syndrome will develop cancer.
Lumc
Hans Vasen practices in Leiden, Netherlands. Mr. Vasen is rated as an Elite expert by MediFind in the treatment of Lynch Syndrome. His top areas of expertise are Lynch Syndrome, Familial Pancreatic Cancer, Familial Colorectal Cancer, Colonoscopy, and Endoscopy.
John Hopper practices in Carlton, Australia. Mr. Hopper is rated as an Elite expert by MediFind in the treatment of Lynch Syndrome. His top areas of expertise are Familial Colorectal Cancer, Lynch Syndrome, Breast Cancer, Oophorectomy, and Salpingo-Oophorectomy.
Dana-Farber Cancer Institute, Inc.
Matthew Yurgelun is an Oncologist in Boston, Massachusetts. Dr. Yurgelun is rated as an Elite provider by MediFind in the treatment of Lynch Syndrome. His top areas of expertise are Lynch Syndrome, Familial Pancreatic Cancer, Pancreatic Cancer, Colonoscopy, and Endoscopy.
Summary: Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Summary: GENPROS aims to analyse the outcomes of patients with rare gene mutations in the cancer predisposition genes, BRCA1, BRCA2, HOXB13, and Lynch Syndrome, after a diagnosis of and treatment for prostate cancer (PCa). The study includes a cohort of gene mutation carriers with PCa matched with a control group of men with PCa who are known not to carry a mutation in the same gene. Clinical data regardin...
Published Date: April 15, 2021
Published By: National Institutes of Health